SEMA6A and nonpapillary renal cell carcinoma: In addition, ICG-001 administration also significantly reversed SEMA6A-induced A498 cell proliferation (Supplementary Fig. 6A), Caspase3/7 activation (Supplementary Fig. 6B) and colony formation in vitro (Supplementary Fig. 6C), suggesting SEMA6A-regualted β-catenin activation is related to ccRCC progression.